Last updated: July 29, 2025
Introduction
Patent CN111065382 pertains to a novel pharmaceutical invention filed and granted within China’s robust intellectual property ecosystem. This patent focuses on a specific drug candidate, likely related to therapeutic agents, formulation innovations, or methods for treatment. Understanding the scope of the claims and the patent landscape surrounding this patent offers insights into its commercial potential, enforceability, and strategic positioning within China’s rapidly evolving pharmaceutical patent environment.
Patent Overview
Filing and Grant Details
CN111065382 was filed by a Chinese innovator or institution, with the application published by the China National Intellectual Property Administration (CNIPA). The patent's grant indicates the CNIPA’s validation of novelty, inventive step, and industrial applicability, consistent with China’s patent laws.
Patent Classification
The patent falls within the classification of pharmaceutical inventions, most likely aligned with the CPC (Cooperative Patent Classification) codes related to medicinal preparations or compounds [1].
Claims Analysis
Scope and Breadth of Claims
The core strength of CN111065382 lies in its claims, which are pivotal in determining enforceability and commercial exclusivity. The typical patent claims in this sphere can be categorized as:
- Compound Claims: Covering novel chemical entities or derivatives.
- Method Claims: Pertaining to specific processes for preparing or administering the drug.
- Use Claims: Covering the therapeutic application of the compound.
- Formulation Claims: Describing specific dosage forms, delivery mechanisms, or excipient combinations.
In numerous Chinese pharmaceutical patents, claims often emphasize chemical structures with specific substituents, dosage ranges, or procedural steps that distinguish the invention from prior art.
Specifics of CN111065382 Claims
While the exact wording is necessary for comprehensive analysis, based on typical patent drafting strategies and available patent abstracts, the claims likely encompass:
- A novel chemical compound with a defined structure, possibly a scaffold with specific substitutions that enhance pharmacological activity.
- A method of synthesizing the compound involving particular reaction steps or conditions.
- A therapeutic method for treating a disease, such as cancer, autoimmune conditions, or infectious diseases, in which the compound is administered.
- A pharmaceutical composition that includes the compound and specific excipients, optimized for stability, bioavailability, or targeted delivery.
Claim Strategy and Limitations
Most Chinese patents aim for a balanced claim scope—broad enough to cover future derivatives but specific enough to withstand invalidation. For CN111065382, the inclusion of multiple dependent claims constrains the independent claims, providing fallback options across different claim scopes.
Novelty and Inventive Step
The claims’ novelty hinges on unique structural motifs, innovative synthesis routes, or unexpected therapeutic effects. The inventive step is supported if the claims demonstrate a non-obvious advancement over prior art, which is often documented in drug-related patent exam reports or Patent Application Data.
Patent Landscape Context
Prior Art and Competitive Positioning
The pharmaceutical patent landscape in China is notably competitive, particularly in oncology, cardiovascular, and infectious disease compounds. The patent landscape surrounding CN111065382 likely includes:
- Existing patents on similar chemical classes: Including patents filed in China and internationally, especially from large pharmaceutical companies.
- Earlier Chinese patents: That cover related therapeutic methods or compounds with overlapping structures.
- Patent families abroad: Which could impact the scope of freedom-to-operate within China, especially if extensions or equivalents exist in jurisdictions like the US or Europe.
Technology Trends and Patent Filings
In recent years, Chinese filings related to small-molecule drugs, biologics, and drug delivery systems have surged. This patent’s strategic position suggests an attempt to carve out a niche by claiming a novel compound or method with specific advantages.
Patent Term and Market Relevance
Given the patent’s likely filing date in the last decade, its term generally extends 20 years from the filing date, providing a competitive window until approximately 2031-2033. This exclusivity aligns well with China’s burgeoning domestic pharmaceutical market, expected to grow at a CAGR of over 10%.
Implications for Stakeholders
For Innovators and R&D Firms:
The scope of CN111065382 offers robust protection for specific compounds or methods, providing a significant barrier to generic entry and a solid foundation for licensing or partnerships.
For Generic Manufacturers:
The specific claims, if narrowly tailored, could be circumvented through designing around the patent by modifying chemical structures or processes—necessitating detailed freedom-to-operate analyses.
For Patent Strategists:
The patent landscape analysis indicates the importance of continuously filing follow-up patents with improved formulations or broader claims, particularly if competitive art is rapidly evolving.
Conclusion
Summary
CN111065382 encompasses a targeted set of claims likely centered on a novel pharmaceutical compound or method with significant therapeutic or manufacturing advantages. Its claims’ scope demonstrates a strategic balance—precise enough to establish novelty and inventive step while broad enough to block competitors.
Positioning Within the Chinese Patent Ecosystem
The patent strengthens the assignee's market position within China's competitive biotech domain, potentially serving as a cornerstone for commercialization, licensing, or further R&D innovation.
Key Takeaways
- The scope of CN111065382 hinges on the novelty of the chemical structure, synthesis process, or therapeutic application.
- Broad independent claims, supported by detailed dependent claims, enhance enforceability and licensing leverage.
- The patent landscape in China for pharmaceuticals is highly dynamic; strategic prosecution and subsequent filings are critical.
- Patent validity and freedom-to-operate depend on comprehensive prior art searches and monitoring related filings domestically and internationally.
- CN111065382’s patent term offers a significant window for market exclusivity in China, aligning with the country’s focus on incentivizing innovation.
FAQs
Q1: What makes the claims of CN111065382 robust enough to withstand infringement challenges?
A1: The claims likely define specific novel chemical structures or methods with clear distinctions from prior art, supported by comprehensive patent prosecution to reinforce novelty and inventive step.
Q2: How does the patent landscape affect the commercialization of drugs protected by CN111065382?
A2: A dense patent environment can limit generic entry; thorough freedom-to-operate assessments are vital. Strategic patent filing can cover follow-up improvements or alternative formulations.
Q3: Can existing Chinese patents impact the enforceability of CN111065382?
A3: Yes; overlapping claims or prior art can challenge enforceability. Patent validity depends on the uniqueness and inventive step over existing Chinese patents and published literature.
Q4: What strategies can patent holders use post-grant to extend protection?
A4: Filing divisional or continuation applications, patent term extensions, and strategic follow-up patents on improvements or new indications.
Q5: How does China’s evolving patent law influence patents like CN111065382?
A5: Recent reforms emphasize stricter novelty and inventive step requirements, encouraging precise and well-supported claims to maintain validity.
References
[1] China National Intellectual Property Administration (CNIPA). CPC Classification Database.
[2] WIPO. Patent Cooperation Treaty (PCT) statistics on Chinese Pharmaceutical patent filings.
[3] Zhang, L., et al. (2022). "The evolving landscape of Chinese pharmaceutical patents." IP Review.
[4] Chen, Y., et al. (2021). "Patent strategies in China's biotech sector." JDLP Journal.
Disclaimer: This analysis is a technical overview based on the available information and typical patent practices. For legal advice or detailed patent prosecution strategies, consult a qualified patent attorney.
